**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 70326

**Manuscript Type:** LETTER TO THE EDITOR

**Use of oral contraceptives and risk of pancreatic cancer in women: A recalculated meta-analysis of prospective cohort studies**

Bae JM. Pancreatic cancer risk of oral contraceptive use

Jong-Myon Bae

**Jong-Myon Bae,** Preventive Medicine, Jeju National University College of Medicine, Jeju-si 63243, Jeju Province, South Korea

**Author contributions:** Bae JM designed and performed the study, analyzed the data and wrote the manuscript.

**Corresponding author: Jong-Myon Bae, MD, PhD, Professor,** Preventive Medicine, Jeju National University College of Medicine, No. 102 Jejudaehak-ro, Jeju-si 63243, Jeju Province, South Korea. jmbae@jejunu.ac.kr

**Received:** July 29, 2021

**Revised:** October 25, 2021

**Accepted: December 23, 2021**

**Published online:**

**Abstract**

In a recent systematic review and meta-analysis of observational studies, the author found potential errors in the selection and extraction processes. The recalculated summary relative risks and the results of a dose-response meta-analysis showed that oral contraceptive use may not be associated with the risk of pancreatic cancer in women.

**Key Words:** Pancreas neoplasms; Oral contraceptives; Risk factor; Meta-analysis; Risk assessment; Systematic review

Bae JM. Use of oral contraceptives and risk of pancreatic cancer in women: A recalculated meta-analysis of prospective cohort studies. *World J Gastroenterol* 2021; In press

**Core Tip:** A systematic review and meta-analysis of observational studies conducted recently concluded that oral contraceptive use was associated with a decreased risk of pancreatic cancer in women. However, the author found potential errors in the selection and extraction processes. The recalculated summary relative risks and the results of a dose-response meta-analysis showed that oral contraceptive use may not be associated with the risk of pancreatic cancer in women. As this conclusion contradicted that reported recently, it is necessary to re-evaluate the direction and statistical significance of this risk through an updated meta-analysis in the future.

**TO THE EDITOR**

I recently read the systematic review and meta-analysis conducted by Ilic *et al*[1] comprising 10 case-control studies and 11 cohort studies, which concluded that the use of oral contraceptives (OCU) was associated with a decreased risk of pancreatic cancer in women (PCW) [summary relative risk (sRR) = 0.85; 95% confidence intervals (CI) = 0.73-0.98; *P* = 0.03]. Interestingly, the subgroup analysis according to the study design showed no statistical significance in case-control studies but showed borderline statistical significance in cohort studies (sRR = 0.84; 95%CI = 0.70-1.00; *P* = 0.05).

However, while reviewing the results of the 11 selected cohort studies, I found the following potential errors. First, among the 11 selected studies, the study by Teras *et al*[2] was a cohort study that analyzed the mortality of PCW; therefore, excluding this study would be valid based on the research hypothesis; second, it would be necessary to include the two cohort studies[3,4] that were considered in other studies on the risk of various cancers associated with OCU[5,6]; finally, in the two studies that did not provide an RR for the ever group[7,8], the RR's direction was opposite to that of the forest plot shown in the study by Ilic *et al*[1].

Considering these issues, I recalculated the sRR of the longest duration (LD) group as well as the ever group. The statistical significance disappeared in both groups, and the sRRs were 1 or higher (Figure 1). Egger’s test was performed to evaluate publication bias, and no statistical significance was noted in either group (*P* = 0.439 and 0.817 in the ever group and LD group, respectively).

Eight of the 12 selected cohorts[3,7-13] provided the information necessary for performing a dose-response meta-analysis. A two-stage random-effects dose-response model was used with a dosing unit of 1 year (*P* of goodness-of-fit = 0.041). The results showed borderline statistical significance with a linear dose-response relationship between OCU duration and PCW risk (sRR = 1.015; 95%CI = 0.999-1.030; *P* = 0.057) (Figure 2).

Based on the results of the recalculated sRRs and DRMA, the OCU may not be associated with the risk of PCW. Because my conclusion contradicts that reported by Ilic *et al*[1], it is necessary to re-evaluate the direction and statistical significance of risk through an updated meta-analysis in the future.

**REFERENCES**

1 **Ilic M**, Milicic B, Ilic I. Association between oral contraceptive use and pancreatic cancer risk: A systematic review and meta-analysis. *World J Gastroenterol* 2021; **27**: 2643-2656 [PMID: 34092981 DOI: 10.3748/wjg.v27.i20.2643]

2 **Teras LR,** Patel AV, Rodriguez C, Thun MJ, Calle EE. Parity, other reproductive factors, and risk of pancreatic cancer mortality in a large cohort of U.S. women (United States). *Cancer Causes Control* 2005; **16:** 1035-40 [DOI: 10.1007/s10552-005-0332-4]

3 **Rosenblatt KA**, Gao DL, Ray RM, Nelson ZC, Wernli KJ, Li W, Thomas DB. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. *Cancer Causes Control* 2009; **20**: 27-34 [PMID: 18704712 DOI: 10.1007/s10552-008-9213-y]

4 **Iversen L**, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. *Am J Obstet Gynecol* 2017; **216**: 580.e1-580.e9 [PMID: 28188769 DOI: 10.1016/j.ajog.2017.02.002]

5 **Wu L**, Zhu J. Linear reduction in thyroid cancer risk by oral contraceptive use: a dose-response meta-analysis of prospective cohort studies. *Hum Reprod* 2015; **30**: 2234-2240 [PMID: 26141711 DOI: 10.1093/humrep/dev160]

6 **Rodriguez-Lara V**, Avila-Costa MR. An Overview of Lung Cancer in Women and the Impact of Estrogen in Lung Carcinogenesis and Lung Cancer Treatment. *Front Med (Lausanne)* 2021; **8**: 600121 [PMID: 34079807 DOI: 10.3389/fmed.2021.600121]

7 **Duell EJ**, Travier N, Lujan-Barroso L, Dossus L, Boutron-Ruault MC, Clavel-Chapelon F, Tumino R, Masala G, Krogh V, Panico S, Ricceri F, Redondo ML, Dorronsoro M, Molina-Montes E, Huerta JM, Barricarte A, Khaw KT, Wareham NJ, Allen NE, Travis R, Siersema PD, Peeters PH, Trichopoulou A, Fragogeorgi E, Oikonomou E, Boeing H, Schuetze M, Canzian F, Lukanova A, Tjønneland A, Roswall N, Overvad K, Weiderpass E, Gram IT, Lund E, Lindkvist B, Johansen D, Ye W, Sund M, Fedirko V, Jenab M, Michaud DS, Riboli E, Bueno-de-Mesquita HB. Menstrual and reproductive factors in women, genetic variation in CYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort. *Int J Cancer* 2013; **132**: 2164-2175 [PMID: 23015357 DOI: 10.1002/ijc.27875]

8 **Lee E**, Horn-Ross PL, Rull RP, Neuhausen SL, Anton-Culver H, Ursin G, Henderson KD, Bernstein L. Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. *Am J Epidemiol* 2013; **178**: 1403-1413 [PMID: 24008905 DOI: 10.1093/aje/kwt154]

9 **Skinner HG**, Michaud DS, Colditz GA, Giovannucci EL, Stampfer MJ, Willett WC, Fuchs CS. Parity, reproductive factors, and the risk of pancreatic cancer in women. *Cancer Epidemiol Biomarkers Prev* 2003; **12**: 433-438 [PMID: 12750238]

10 **Navarro Silvera SA**, Miller AB, Rohan TE. Hormonal and reproductive factors and pancreatic cancer risk: a prospective cohort study. *Pancreas* 2005; **30**: 369-374 [PMID: 15841050 DOI: 10.1097/01.mpa.0000160301.59319.ba]

11 **Kabat GC**, Kamensky V, Rohan TE. Reproductive factors, exogenous hormone use, and risk of pancreatic cancer in postmenopausal women. *Cancer Epidemiol* 2017; **49**: 1-7 [PMID: 28521283 DOI: 10.1016/j.canep.2017.05.002]

12 **Butt SA**, Lidegaardi Ø, Skovlund C, Hannaford PC, Iversen L, Fielding S, Mørch LS. Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. *PLoS One* 2018; **13**: e0206358 [PMID: 30376560 DOI: 10.1371/journal.pone.0206358]

13 **Michels KA**, Brinton LA, Pfeiffer RM, Trabert B. Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health Study. *Am J Epidemiol* 2018; **187**: 1630-1641 [PMID: 29394309 DOI: 10.1093/aje/kwx388]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 29, 2021

**First decision:** October 16, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** South Korea

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Tung TH **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**

****

**Figure 1 Forest plots in the ever and the longest duration group.**

****

**Figure 2 The linear dose-response relationship between duration (year) of oral contraceptive usage and risk of pancreatic cancer in women.** RR: Relative risk.